Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olprinone
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Olprinone is a selective phosphodiesterase 3 inhibitor developed as a cardiotonic agent. It exerts positive inotropic and vasodilatory effects by increasing intracellular cyclic AMP (cAMP) levels in both cardiomyocytes and vascular smooth muscle cells, leading to increased myocardial contractility and reduced vascular resistance. Olprinone is primarily indicated for the treatment of acute heart failure and has been marketed in Japan since 1996. Additional pharmacological actions include augmentation of cerebral blood flow, inhibition of platelet aggregation, anti-inflammatory activity, bronchodilation, improvement of microcirculation, and attenuation of oxidative injury[1][3][5][6][7].
- Brand names
- Loprinone
- Other names
- olprinone hydrochlorideolprinone hydrochloride hydrate
02
Targets
PDE3
Beyond the preview
Go deeper on olprinone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olprinone.